Pulmatrix, Inc.

NasdaqCM:PULM

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 25.24 M

Share Price

USD 6.91

Avg Daily Volume

18,568

Change (1 day)

-7.00%

Change (1 year)

248.99%

Change (YTD)

-1.00%

Pulmatrix, Inc. Dividend Yield on June 23, 2025

Pulmatrix, Inc. Dividend Yield is NA on June 23, 2025. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Pulmatrix, Inc. 52-week low Dividend Yield is 0.00% on June 23, 2025, which is NA below the current Dividend Yield.
Pulmatrix, Inc. 52-week low Dividend Yield is 0.00% on June 23, 2025, which is NA below the current Dividend Yield.
Pulmatrix, Inc. average Dividend Yield for the last 52 weeks is 0.00%.

Daily

From:

To:

Zoom:

Key data

Date	Dividend Yield	Market Capitalization	Share Price	Share Price

NasdaqCM: PULM

Pulmatrix, Inc.

CEO	Mr. Peter Ludlum CMA, MBA
IPO Date	March 21, 2014
Location	United States
Headquarters	99 Hayden Avenue
Employees	2
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.